Recombinant factor  XIII prophylaxis is safe and effective in young children with congenital factor XIII‐A deficiency: international phase 3b trial results

ConclusionsConsistent with data from older age groups, prophylaxis with rFXIII appears to be safe and effective in young children with congenital FXIII A‐subunit deficiency.

Source: Journal of Thrombosis and Haemostasis - July 10, 2017 Category: Hematology Authors: B. A. Kerlin, A. Inbal, A. Will, M. Williams, M. ‐L. Garly, L. Jacobsen, S. L. Kearney Tags: Brief Report Source Type: research